{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/meningitis-bacterial-meningitis-meningococcal-disease/management/non-blanching-rash-or-meningococcal-septicaemia/","result":{"pageContext":{"chapter":{"id":"1b657d07-eb89-5d3b-9404-ef623a716920","slug":"non-blanching-rash-or-meningococcal-septicaemia","fullItemName":"Scenario: Non-blanching rash or meningococcal septicaemia","depth":2,"htmlHeader":"<!-- begin field 51e1e777-594f-4de9-8873-fdf740bda116 --><h2>Scenario: Non-blanching rash or meningococcal septicaemia</h2><!-- end field 51e1e777-594f-4de9-8873-fdf740bda116 -->","summary":"Covers the pre-hospital management of suspected bacterial meningitis with non-blanching rash or meningococcal septicaemia.","htmlStringContent":"<!-- begin item 471785be-87e7-4fe9-ae58-4344c6609087 --><!-- begin field ee00e1da-5d61-4428-bc55-acd900ac5edb --><p>From birth onwards.</p><!-- end field ee00e1da-5d61-4428-bc55-acd900ac5edb --><!-- end item 471785be-87e7-4fe9-ae58-4344c6609087 -->","topic":{"id":"5c52d7ca-c2cb-5551-ba9f-1fcdbdf1faad","topicId":"b3676823-9bef-422c-a1fe-011ca9f6883f","topicName":"Meningitis - bacterial meningitis and meningococcal disease","slug":"meningitis-bacterial-meningitis-meningococcal-disease","lastRevised":"Last revised in July 2020","chapters":[{"id":"12319bd7-3980-5b0c-8deb-b4351ef52f99","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c72ab6e0-adbe-5cb4-9d67-4909820fb847","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f9d67392-74e7-5adf-b712-fa42f7e69711","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"af144a12-5e1e-5d97-8d14-45db380ecef0","slug":"changes","fullItemName":"Changes"},{"id":"eb9e7802-cda3-5c04-b178-4ae4c2bb0003","slug":"update","fullItemName":"Update"}]},{"id":"9719c30a-3d48-51f7-8a76-d9a376cfc395","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"34af18fa-646e-5799-8eea-3070c9be3955","slug":"goals","fullItemName":"Goals"},{"id":"d1170912-4321-588d-88ca-217aea38c5c4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"777fba00-f0b7-56ca-aad8-482a8107aa53","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6162c8c1-72d4-5418-b083-e9261dc043af","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8b16062f-23c7-57ef-9c04-d8696d43c468","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"141459fa-eb5f-51e0-a4f1-55aa8fcf568a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"45808ab8-48c2-500e-904e-b28b1dd9f2c1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a71886c1-a30d-566c-84b9-d1fd02dbacd0","slug":"definition","fullItemName":"Definition"},{"id":"3bf2ba08-2574-58c3-9147-499dd2671f06","slug":"causes","fullItemName":"Causes"},{"id":"9d242c7b-d3c1-5081-8db2-1d366c43c71d","slug":"transmission","fullItemName":"Transmission"},{"id":"46f40806-a5d8-5742-ad5b-35abf21b89bb","slug":"prevalence","fullItemName":"Prevalence"},{"id":"20fadd0c-adea-5cb2-8cb7-cc9df62dd094","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6f81c33d-8bac-5747-bd44-5b3244f57b58","slug":"complications","fullItemName":"Complications"},{"id":"6e9b6946-ed39-54a6-9e90-9989f22e636b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"5bcb31df-47de-5f61-bdb9-90d4ff02c6c4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"eeb07a78-3dda-516a-943d-8418d5224628","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"5644216d-a652-51b5-a696-c9e4aac4b609","slug":"assessing-the-rash","fullItemName":"Assessing the rash"},{"id":"2fb8dc81-2176-50e5-a2c5-1bb1541cddfc","slug":"assessing-vital-signs","fullItemName":"Assessing vital signs"},{"id":"0f916e0f-ed47-5988-843a-19af47c3726d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"75dbccb7-b3c5-51dc-8069-f497798fd646","fullItemName":"Management","slug":"management","subChapters":[{"id":"1b657d07-eb89-5d3b-9404-ef623a716920","slug":"non-blanching-rash-or-meningococcal-septicaemia","fullItemName":"Scenario: Non-blanching rash or meningococcal septicaemia"},{"id":"414935f6-7030-5ea4-a397-cac8958da2c7","slug":"without-non-blanching-rash","fullItemName":"Scenario: Without non-blanching rash"},{"id":"d532e29d-6fc3-54b3-b286-b1e80ce7840c","slug":"managing-close-contacts","fullItemName":"Scenario: Managing close contacts"},{"id":"81e1e9d4-a4c9-5c10-80d9-07cc83d6dba2","slug":"follow-up-after-hospital-discharge","fullItemName":"Scenario: Follow up after hospital discharge"}]},{"id":"c620569e-fa7a-5c2c-a708-ec6432bf5c51","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9f59f8a5-e555-56ba-861a-a492cfe5a298","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9c42a3ff-6a45-5e6c-a247-51a81848f67a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"50077a62-1fb9-5968-a1e6-71ac64bcf7e1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e85d7bc-8751-5e8f-8e77-8b91b0cf1141","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7fb74eaa-420c-5cdd-a04e-92cbd9be478c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b8d54b7e-8c9b-5d53-8a0a-6a7296727eb4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"71898679-d838-5f6d-8422-64c378e43045","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"75dbccb7-b3c5-51dc-8069-f497798fd646","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"8fb39f15-4c1f-5114-87ee-e0a964db8d2d","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field cba059ca-9172-4955-a600-e7804c84cc8c --><h3>How should I manage suspected bacterial meningitis with a non-blanching rash or meningococcal septicaemia?</h3><!-- end field cba059ca-9172-4955-a600-e7804c84cc8c -->","summary":null,"htmlStringContent":"<!-- begin item d264ba5f-7edf-4326-a8ca-08660b59709c --><!-- begin field c54e04cf-f865-4bd6-845f-67d37b6fda14 --><ul><li><strong>Arrange emergency medical transfer to hospital by telephoning 999.</strong></li><li><strong>Administer a single dose of parenteral benzylpenicillin (intravenously or intramuscularly) at the earliest opportunity, but do not delay urgent transfer to hospital. </strong><br><ul><li>If given intramuscularly, it should be given as proximally as possible — preferably into a part of the limb that is still warm (as cold areas will be less well perfused). </li><li>Dosage: <ul><li>Children younger than 1 year of age — 300 mg.</li><li>Children 1–9 years of age — 600 mg.</li><li>Adults and children 10 years of age or older — 1200 mg.</li></ul></li><li>Benzylpenicillin should be carried in GP emergency bags. </li><li>Paramedics also have the mandate to give benzylpenicillin for suspected meningococcal disease.</li></ul></li><li><strong>Withhold benzylpenicillin if the person has a clear history of penicillin anaphylaxis</strong> (a history of a rash following penicillin is not a contraindication). </li></ul><!-- end field c54e04cf-f865-4bd6-845f-67d37b6fda14 --><!-- end item d264ba5f-7edf-4326-a8ca-08660b59709c -->","subChapters":[{"id":"eed43a9b-419f-59d3-8b41-d357b269b399","slug":"basis-for-recommendation-15e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 73a4e04e-2b58-4006-8c1c-874dc775547c --><h4>Basis for recommendation</h4><!-- end field 73a4e04e-2b58-4006-8c1c-874dc775547c -->","summary":null,"htmlStringContent":"<!-- begin item 15e8f69d-a47c-4116-a807-f8d02820b09e --><!-- begin field 43716c8d-9d0a-4b7c-97a1-30574687d4ff --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Bacterial meningitis and meningococcal septicaemia in children </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/references/\">NICE, 2018</a>], the Meningitis Research Foundation (MRF) booklet <em>Meningococcal meningitis and sepsis. Guidance notes: diagnosis and treatment in general practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/references/\">Meningitis Research Foundation, 2018</a>], and the <em>British National Formulary (BNF)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/references/\">Joint Formulary Committee, 2020</a>].</p><h5>Alternative pre-hospital parenteral antibiotic in people with penicillin allergy</h5><ul><li>NICE does not recommend specific parenteral antibiotics for children or young people who have a clear history of penicillin anaphylaxis. The priority is urgent transfer to hospital.</li><li>The<em> UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults</em> recommends that if an antibiotic is given in primary care it should be benzylpenicillin or a third-generation cephalosporin such as cefotaxime or ceftriaxone and that in the case of known anaphylaxis to penicillins or cephalosporins, antibiotics should not be given until the person is admitted to hospital [<a class=\"bibliography-reference internal-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/references/\">McGill, 2016a</a>]. </li><li>An Irish guideline from the Health Protection Surveillance Centre (HPSC) <em>Guidelines for the early clinical and public health management of bacterial meningitis (including meningococcal disease)</em> recommends ceftriaxone or cefotaxime as alternatives to benzylpenicillin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/references/\">HPSC, 2016</a>].</li><li>The MRF advises that while benzylpenicillin is recommended for pre-hospital administration cefotaxime can be given as an alternative [<a class=\"bibliography-reference internal-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/references/\">Meningitis Research Foundation, 2018</a>].</li></ul><!-- end field 43716c8d-9d0a-4b7c-97a1-30574687d4ff --><!-- end item 15e8f69d-a47c-4116-a807-f8d02820b09e -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}